Ars Technica
Jan Janisch-Hanzlik's MS was wrecking her life, so she became the first patient in a CAR T trial - now the cancer therapy is being repurposed to fight autoimmune diseases, with promising results and a few existential risks.
The Good Times
One sardonic roundup, delivered on your schedule. Free. Unsubscribe whenever your tolerance for wit runs out.
Already subscribed but we never reach your inbox? Check your spam folder and hit 'Not spam' (or 'Remove from spam') to bust us out of junk-mail purgatory. You'll be helping everyone else too.
The Good Times
One sardonic roundup, delivered on your schedule. Free. Unsubscribe whenever your tolerance for wit runs out.
Already subscribed but we never reach your inbox? Check your spam folder and hit 'Not spam' (or 'Remove from spam') to bust us out of junk-mail purgatory. You'll be helping everyone else too.
Don't open any of our emails for a month and you'll be automatically removed from the mailing list.